Digital Payer Portals for Enhanced Value Communication
The trend of using digital tools for communication and information sharing in the life science…
Certara2024 年 8 月 9 日
Using Real-world Evidence to Advance Market Access for New Therapeutics
Jim Gallagher2021 年 9 月 29 日
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…
Jim Gallagher2021 年 9 月 23 日
Succeeding in Value Communication: Introduction
Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…
Certara2021 年 8 月 5 日
What is BaseCase?
Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…
Certara2021 年 7 月 20 日
Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers
This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…
Certara2021 年 6 月 18 日
Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
Jim Gallagher2021 年 6 月 11 日
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
Jim Gallagher2021 年 6 月 11 日
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021 年 5 月 26 日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021 年 5 月 26 日
